Rex Bionics develops and produces exoskeletons to help assist in the rehabilitation and improve the mobility of patients with spinal cord injury and other lower-limb mobility problems. In this interview CEO Crispin Simon explains the product, the markets Rex is targeting and sets out the company’s investment case. He points to the start of clinical trials and entry to new markets as inflection points which may be reached in 2015.